<DOC>
	<DOCNO>NCT01410565</DOCNO>
	<brief_summary>This international , multicenter , double-blind , placebo-controlled , randomize study . All eligible patient enter open label phase study receive single immediate instillation apaziquone ( 4 mg 40 mL diluent ) , post transurethral resection-bladder tumor ( TURBT ) . Following Central Pathology review histology Double Blind Phase qualification , patient confirm eligibility randomize receive either 6 weekly intravesical instillation apaziquone match placebo undergo cystoscopic safety assessment every 3 month 24 month randomization . Patients histologic evidence recurrent disease study treat accord current treatment guideline local standard care . Safety efficacy assessment perform 3 month interval randomize patient throughout study . Patients receive single dose apaziquone immediately follow TURBT eligible randomization follow 3 month cystoscopic exam safety assessment .</brief_summary>
	<brief_title>Efficacy Safety Multi-Instillations Apaziquone Patients With Non-Muscle Invasive Bladder Cancer</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Apaziquone</mesh_term>
	<criteria>Open Phase 1 . Has patient give write informed consent patient willing able abide protocol ? 2 . Is patient 18 year old ? 3 . If patient female childbearing potential , use acceptable/effective method contraception ? 4 . Does female patient childbearing potential negative serum pregnancy test screening ? 5 . Does patient clinically apparent primary recurrent low grade Ta NMIBC : multiple tumor ( 27 ) No single Tumor &gt; 3 cm No history / evidence Tis Or patient clinically apparent primary recurrent high grade Ta NMIBC : A single tumor ≤ 3 cm No history / evidence Tis 6 . Is patient able retain bladder instillation minimum 60 minute ? 7 . Did patient upper urinary tract evaluation exclude urothelial carcinoma , hydronephrosis renal cell carcinoma renal cancer 6 month prior study screen ? 8 . Is patient 's urethra ( include prostatic urethra men ) endoscopically free visible TCC ? 9 . For patient recurrent tumor , patient least 6month cystoscopicallyconfirmed tumorfree interval last tumor recurrence time screen ? 10 . Has male patient prostate specific antigen ( PSA ) 4 10 ng/mL diagnostic evaluation reasonably exclude diagnosis prostate cancer opinion Investigator ? DoubleBlind Phase 1 . Was visible tumor resect initial TURBT ? 2 . Does Central Pathology review patient 's bladder tumor confirm : Low grade Ta disease multiple tumor ( 2 7 ) High Grade Ta disease single tumor No microscopic evidence lymphovascular invasion and/or evidence tumor thromboemboli Open Phase 1 . Has patient receive previous pelvic radiotherapy ( include external beam and/or brachytherapy ) ? 2 . Has patient ever receive apaziquone ? 3 . Has patient receive induction course ( complete 5 6 scheduled weekly instillation ) intravesical BCG ( ± interferon ) last dose give less 12 month ago ? 4 . Has patient prior intravesical chemotherapy , exclusive singledose adjuvant intravesical chemotherapy immediately postTURBT ? 5 . Does patient history urinary retention post void residual ≥ 250 cc bladder scan ultrasound ( post void residual test may repeat 3 time ) ? 6 . Does patient patient bladder tumor histology transitional cell carcinoma ? 7 . Does patient patient micropapillary transitional cell carcinoma ? 8 . If patient recurrent papillary disease bladder , pathology anything pTa past ? 9 . Does patient active urinary tract infection confirm culture document history recurrent UTI ( ≥ 6 female ≥2 male per year ) prior 2 year ? 10 . Does patient bleed disorder screen platelet count &lt; 50 x 109/L ? 11 . Does patient screen hemoglobin &lt; 10 mg/dL ? 12 . Does male patient serum PSA &gt; 10 ng/mL ? 13 . Does patient history Acquired Immunodeficiency Syndrome HIV positive ? 14 . Does patient condition concurrent severe and/or uncontrolled medical psychiatric disease ( e.g. , uncontrolled diabetes , decompensated congestive heart failure , myocardial infarction within 6 month study , unstable uncontrolled hypertension , active uncontrolled infection ) , could compromise participation , compliance schedule visit and/or completion study ? 15 . Has patient participate investigational protocol within past 90 day ? 16 . Is patient pregnant breast feeding ? 17 . Does patient life expectancy &lt; 3 year ? 18 . Has patient malignancy receive therapy malignancy last five year except nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma undetectable PSA ≥1 year follow definitive therapy localize prostate cancer ? 19 . Does patient document vesicoureteral reflux indwell ureteral stent ? 20 . Does patient tumor bladder diverticulum ? 21 . Does patient know allergy red color food dye ?</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bladder Cancer</keyword>
	<keyword>Non-Muscle Invasive Bladder Cancer</keyword>
	<keyword>NMIBC</keyword>
	<keyword>Apaziquone</keyword>
	<keyword>EOquin</keyword>
	<keyword>GU Cancer</keyword>
	<keyword>TURBT</keyword>
</DOC>